(Q38432923)

3 September 2017

title

Clinical correlates of JAK2V617F allele burden in essential thrombocythemia (English)

1 reference

3 September 2017

Ayalew Tefferi

1 reference

3 September 2017

Jaya Kittur

1 reference

3 September 2017

Ryan A Knudson

1 reference

3 September 2017

Terra L Lasho

1 reference

3 September 2017

Christy M Finke

1 reference

3 September 2017

Naseema Gangat

1 reference

3 September 2017

Alexandra P Wolanskyj

1 reference

3 September 2017

Chin-Yang Li

1 reference

3 September 2017

Wenting Wu

1 reference

3 September 2017

Rhett P Ketterling

1 reference

3 September 2017

Animesh Pardanani

1 reference

3 September 2017

language of work or name

English

0 references

publication date

1 June 2007

1 reference

3 September 2017

1 reference

3 September 2017

volume

109

1 reference

3 September 2017

1 reference

3 September 2017

page(s)

2279-2284

1 reference

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22663

A gain-of-function mutation of JAK2 in myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22663

7 January 2021

The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22663

7 January 2021

JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22663

7 January 2021

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22663

7 January 2021

JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22663

7 January 2021

Clinical implications of the JAK2 V617F mutation in essential thrombocythemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22663

7 January 2021

The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22663

7 January 2021

Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22663

7 January 2021

X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22663

7 January 2021

Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22663

7 January 2021

Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22663

7 January 2021

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22663

7 January 2021

Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22663

7 January 2021

Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22663

7 January 2021

Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22663

7 January 2021

Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22663

7 January 2021

The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22663

7 January 2021

Long-term serial analysis of X-chromosome inactivation patterns and JAK2 V617F mutant levels in patients with essential thrombocythemia show that minor mutant-positive clones can remain stable for many years

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22663

7 January 2021

Mutation studies in CD3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2(V617F) in granulocytes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22663

7 January 2021

Identifiers

DOI

10.1002/CNCR.22663

1 reference

3 September 2017

1 reference